跳至主要内容
临床试验/NCT04479514
NCT04479514已完成2 期

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Dana-Farber Cancer Institute4 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2020年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
14
试验地点
4
主要终点
Rate of Cutaneous Reaction

研究概览

简要总结

This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.

详细描述

This prospective, single-arm phase 2 clinical trial is looking at whether gentle skin care, sun protection and dilute bleach baths might decrease the chances or the severity of skin changes that occur during treatment for brain tumors.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

Participants will receive a study treatment regimen that involves a daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants enrolled in this study, will be in this research study during the course of their anti-cancer treatment and receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of anti-cancer treatment, and at twelve weeks after the start of anti-cancer treatment.

Participants will be followed for twelve weeks.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with a brain tumor between ages 6 months old -18 years old and will undergo treatment with at least one of the following:
  • Targeted BRAF inhibitor therapy to treat the brain tumor
  • Targeted MEK inhibitor therapy to treat the brain tumor
  • Targeted pan-RAF inhibitor therapy to treat the brain tumor
  • Subjects may participate in other studies, including therapeutic trials.
  • Ability to comply with PSCR including sun protection, gentle skin care and every other day dilute bleach baths.
  • Ability to understand and/or the willingness of their parent or legally authorized representative to sign a written informed consent document.

排除标准

  • Diagnosed with brain tumor at > 18 years old
  • No data in medical records regarding treatment exposures
  • Treated with a BRAF, MEK or pan-RAF inhibitor in the last three months
  • Past or present allergic reaction to bleach
  • Past or present allergic reactions to sunscreen and/or creams, lotions, emollients to be utilized in this study

研究组 & 干预措施

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: Warm Baths or Showers (Other)

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: Moisturizer (Other)

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: SPF 30 or Higher Suncreen (Drug)

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: Sun Protective Clothing (Other)

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: Limited Sun Exposure (Behavioral)

Preventative Skin Care Routine

Experimental

Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.

Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment.

干预措施: Dilute bleach baths (Other)

结局指标

主要结局

Rate of Cutaneous Reaction

时间窗: 12 weeks

Proportion (percentage) of patients with one or more cutaneous reaction to targeted BRAF, MEK, or Pan-RAF inhibitor therapy

次要结局

  • Overall Cutaneous Reaction Severity(12 weeks)
  • Xerosis Severity(12 weeks)
  • Hand Foot Syndrome Severity(12 weeks)
  • Pediatric Quality of Life(12 weeks)
  • Children's Dermatology Quality of Life(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jennifer Huang, MD

Principal Investigator

Dana-Farber Cancer Institute

研究点 (4)

Loading locations...

相似试验